Your Best Stock

Moderna MRNA

US equityMarket cap rank #227Infectious Disease
$183.47
+$1.36 (+0.75%)
Market open · Sep 24, 1:10 pm ET
After hours $181.30 -0.44%
Open$180.60
Prev close$182.11
Day range$180.39 – $189.22
Volume8.01M
Market cap$73.25B
P/E (TTM)
Dividend yield

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).

MRNA at a glance

Shares of Moderna are up 0.75% at $183.47. The company is worth $73.25B, number 227 out of 300 on our list.

Over the past 52 weeks it has traded between $22.28 and $192.31, so it sits 4.6% below the top of that range. Holders are ahead 608.9% over twelve months, and up 203.7% across the last three months.

On the chart it holds above both the 50-day ($104.93) and 200-day ($62.58) moving averages; RSI is 73, which some call overbought, and the last 30 sessions moved at roughly 316% annualized volatility.

In the quarter ended Jun 2026 the company brought in $143.00M of revenue, up 4.4% from a year earlier, and a net loss of $782.00M.

13 analysts follow the stock and the average call is "hold". The mean target, $113.40, sits 38.2% under where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Moderna: the business

Moderna develops vaccines and treatments based on mRNA technology, and became known for its COVID-19 vaccine.

What tends to move it. Declining COVID vaccine sales, cost cuts and the outcome of flu and cancer vaccine trials shape the stock, and it burns cash.

Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
+0.7%
1 week
+26.0%
1 month
+32.1%
3 months
+203.7%
6 months
+257.4%
Year to date
+522.1%
1 year
+608.9%
Day range
$180.39$189.22
52-week range
$22.28$192.31

Technical signals

Full technicals →
Trend readStrong uptrend

5 bullish · 0 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average+21.7%Bullish
Price vs 50-day average+74.8%Bullish
Price vs 200-day average+193.2%Bullish
50-day vs 200-day50d above 200dBullish
RSI (14)72.9Neutral
MACD (12,26,9)18.28Bullish
Bollinger band position108%Neutral

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

Key statistics

Bid / Ask$183.31 / $183.64
Average price today$185.30
Volume8.01MAvg (90d) 13.75M
Turnover$1.48B
Turnover rate2.15%of shares outstanding
Volume ratio0.69vs. recent average pace
Day amplitude4.85%
Market cap$73.25B
Float market cap$68.30B
Shares outstanding372.26M
EPS (TTM)-$7.26
P/B10.83
Book value / share$16.94
Earnings yield-0.47%
Net profit (TTM)-$2.90B
Net assets$6.76B
30-day volatility315.6%annualized
Avg daily range (ATR)6.18%of price, 14 days
Max drawdown (1y)-34.2%-1.0% from 1y peak

Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

How MRNA ranks on BeStock

Market value#227 of 300
Closeness to 52-week high#33 of 300
Dollar volume today#25 of 300

Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.

Latest reported quarter: Q2, ended Jun 2026

Revenue$143.00M+4.4% YoY
Operating profit-$815.00M+10.1% YoY
Net profit-$782.00M+5.2% YoY
Diluted EPS-$1.97+7.5% YoY
Free cash flow-$563.00M+38.9% YoY
Operating cash flow-$526.00M

Revenue, last 8 quarters

$1.9BSep '24$956.0MDec '24$107.0MMar '25$137.0MJun '25$1.0BSep '25$676.0MDec '25$389.0MMar '26$143.0MJun '26

Net profit, last 8 quarters

$13.0MSep '24$-1.1BDec '24$-971.0MMar '25$-825.0MJun '25$-200.0MSep '25$-826.0MDec '25$-1.3BMar '26$-782.0MJun '26

Profitability & balance sheet

Gross margin22.8%
Operating margin-150.2%
Net margin-142.6%
Return on equity-39.0%
Return on assets-27.4%
Return on invested capital-36.2%
Current ratio2.29
Liabilities / assets38.3%
Cash & investments$5.14B
Total debt$1.24B
Net cash (debt)$3.90B

Where the revenue comes from

Quarter 2026/Q2

By business line

  • COVID$91.00M 62.8%
  • Other revenue$51.00M 35.2%
  • Respiratory syncytial virus (RSV)$3.00M 2.1%
Average move on report day±6.1%last 16 reports
Closed higher6 of 1638% of the time
Best reaction+13.5%
Worst reaction-21.0%

Stock move on the day after each report

-3.0%2024/Q3+3.4%2024/Q4-5.3%2025/Q1-6.6%2025/Q2+3.3%2025/Q3+5.3%2025/Q4-1.2%2026/Q1-5.4%2026/Q2

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Valuation

Multiples measured against the stock's own five-year history

Valuation detail →
Price / earnings-18.0x
CheapRich

Near the bottom of its 5-year range · 1st percentile, 5-year average 2.2x

Price / book8.5x
CheapRich

Near the top of its 5-year range · 93rd percentile, 5-year average 3.6x

#4755 of 5304 stocks by PB (1 = cheapest)

Price / sales25.8x
CheapRich

Near the top of its 5-year range · 99th percentile, 5-year average 5.7x

#4721 of 5143 stocks by PS (1 = cheapest)

P/E over five years

-24x4x31x59xSep '21Mar '24Sep '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$163.00
Price vs. fair value+12.6%Trading above the estimate
Star rating★★★☆☆
UncertaintyVery High

Analyst view

All ratings →
ConsensusHold
Analysts13
Average target$113.40-38.2% vs. price
  • Buy 23%
  • Hold 62%
  • Sell 15%
Low $60.00Now $183.47Avg $113.40High $180.00

Latest rating actions

  • 11 Sep 2026DBSHOLD · PT $150.00
  • 3 Sep 2026Rothschild & Co RedburnSELL · PT $81.00
  • 27 Aug 2026Argus ResearchBUY · PT $180.00
  • 25 Aug 2026Wolfe ResearchHOLD
  • 21 Aug 2026J.P. MorganSELL · PT $77.00

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Ownership detail →
Institutional ownership80.6%-2.32 pts vs. prior quarter
Institutions holding938-2 vs. prior quarter
Insider trades (recent)10 buys / 6 sellsNet buying
Short interest9.81% of floatDays to cover 1.0 · as of 31 Aug 2026
Short-sale volume share17.3%5-day average of daily volume

Short-sale volume as % of daily volume

12%15%18%21%Aug '26Sep '26Sep '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$224.21M (9 inflow days, 11 outflow days).

Latest headlines

More news →
  • Beta Pharma (300558.SZ): Currently has no relevant layout in the mRNA field.Gelonghui Finance · 9 Sep 2026
  • HK Stock Market Alert | Jitai Technology-P (07666) surges over 20% in afternoon session; cumulative gain exceeds 30% in two days of inclusion in the Stock Connect. Global AI + mRNA vaccine sector accelerates.Zhitong Finance · 8 Sep 2026
  • Hualan Biological Engineering Inc. (002007.SZ): Controlled subsidiary receives approval notice for clinical trials of novel influenza mRNA vaccineGelonghui Finance · 7 Sep 2026
  • Nano Holdings: New research findings on mRNA therapeutics have been announced by the group led by Professor Akihisa Iitaka.JPX · 4 Sep 2026
  • DBS Maintains Moderna(MRNA.US) With Hold Rating, Raises Target Price to $150Market news · 12 Sep 2026
  • Form 144 | Moderna(MRNA.US) Officer Proposes to Sell 4.69 Million in Common StocksMarket news · 10 Sep 2026

MRNA stock: common questions

What is MRNA's latest share price?

$183.47 is the latest print for MRNA, a move of +0.75% against yesterday's close of $182.11. Today's low and high so far: $180.39 and $189.22.

What is MRNA worth in total?

Equity value comes to $73.25B at the current price. By that measure it is number 227 of the 300 names in our coverage.

Where does MRNA sit in its 52-week range?

The year's floor is $22.28 and the ceiling $192.31. Shares are 4.6% away from that ceiling.

Does MRNA send cash back through a dividend?

Our data shows no dividend paid by Moderna over the trailing twelve months.

What is the analyst view on Moderna?

Of 13 analysts, 23% say buy, 62% hold and 15% sell. Price targets average $113.40, with the most cautious at $60.00 and the most optimistic at $180.00.

What does Moderna do?

Moderna develops vaccines and treatments based on mRNA technology, and became known for its COVID-19 vaccine.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Scroll to Top